Minimal residual disease based on patient specific Flt3-ITD and -ITT mutations in acute myeloid leukemia

Leuk Res. 2005 Jul;29(7):849-53. doi: 10.1016/j.leukres.2004.12.001.

Abstract

We present our first experiences with determination of minimal residual disease (MRD) based on patient specific Flt3-ITD (internal tandem duplication) mutations. We analysed MRD status of 11 AML patients in a retrospective investigation and its potential impact on the follow up of these patients. In five out of six patients with a positive Flt3-ITD based MRD status a relapse of AML was observed in the follow up while one patient lacks a clinical relapse so far. In contrast, four out of five patients with a negative MRD status remain free of disease. One of these patients relapsed with a switch of FAB subtype including loss of Flt3-ITD mutation. Furthermore, in one patient we could identify a Flt3-ITT (internal tandem triplication mutation).

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Bone Marrow / pathology
  • Female
  • Gene Duplication*
  • Humans
  • Karyotyping
  • Leukemia, Myeloid, Acute / genetics*
  • Male
  • Middle Aged
  • Mutation*
  • Neoplasm, Residual / genetics*
  • Proto-Oncogene Proteins / genetics*
  • Receptor Protein-Tyrosine Kinases / genetics*
  • Recurrence
  • Retrospective Studies
  • Treatment Outcome
  • fms-Like Tyrosine Kinase 3

Substances

  • Proto-Oncogene Proteins
  • FLT3 protein, human
  • Receptor Protein-Tyrosine Kinases
  • fms-Like Tyrosine Kinase 3